Company intelligence / Profile preview

CloudCath

San Francisco, California, United Statescloudcath.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CloudCath’s system has demonstrated the ability to provide early detection of peritoneal dialysis complications, such as infection and peritonitis, by continuously analyzing dialysate effluent in real time. The company claims its technology could reduce infection-driven hospitalizations by up to 75%, potentially saving thousands of lives and reducing healthcare costs significantly. Clinical studies are ongoing or planned; full commercial launch is pending regulatory clearance.

Therapeutic areas: Nephrology
Modalities: DeviceNon-pharmacological therapy (remote monitoring)
Industry: Physiological Monitoring

Partnerships

American Renal Associates (collaboration on pre-market clinical study for peritoneal dialysis patients)

Beyond the preview

Go deeper on CloudCath.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CloudCath.

Explore the full profile